Ronald E. Blaylock's most recent trade in W.R. Berkley Corp. was a trade of 3,090 Common Stock done . Disclosure was reported to the exchange on June 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| W.R. Berkley | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2026 | 3,090 | 121,990 (0%) | 0% | 0 | Common Stock | |
| Pfizer | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2026 | 7,686 | 84,012 | - | - | Phantom Stock Units | |
| W.R. Berkley | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 2,776 | 118,900 (0%) | 0% | 0 | Common Stock | |
| Pfizer | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 8,999 | 71,373 | - | - | Phantom Stock Units | |
| Pfizer | Ronald E. Blaylock | Director | Purchase of securities on an exchange or from another person at price $ 25.65 per share. | 13 Feb 2025 | 19,457 | 27,707 (0%) | 0% | 25.6 | 499,072 | Common Stock |
| CarMax | Ronald E. Blaylock | Director | 01 Jul 2024 | 2,598 | 12,658 (0%) | 0% | 0 | Common Stock | ||
| W.R. Berkley | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,534 | 77,416 (0%) | 0% | 0 | Common Stock | |
| Pfizer | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 8,115 | 58,627 | - | - | Phantom Stock Units | |
| CarMax | Ronald E. Blaylock | Director | 30 Jun 2023 | 2,210 | 10,060 (0%) | 0% | 0 | Common Stock | ||
| W.R. Berkley | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 3,479 | 74,882 (0%) | 0% | 0 | Common Stock | |
| Pfizer | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 5,291 | 47,972 | - | - | Phantom Stock Units | |
| CarMax | Ronald E. Blaylock | Director | 01 Jul 2022 | 1,996 | 7,850 (0%) | 0% | 0 | Common Stock | ||
| W.R. Berkley | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,995 | 71,404 (0%) | 0% | 0 | Common Stock | |
| Advantage Soln Inc (Class A) | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 40,603 | 90,303 | - | 0 | Class A Common Stock | |
| Pfizer | Ronald E. Blaylock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 4,058 | 41,235 | - | - | Phantom Stock Units |